Cart Cell Therapy Market to Exhibit a CAGR of 29.4% during the Forecast Period | Key Players: Novartis AG, Kite Pharma, Mustang Bio, Sorrento Therapeutics, CARsgen Therapeutics

The global cart cell therapy market was worth USD 355.1 million in 2018, and it is expected to expand at a CAGR of 29.4% over the next five years. The global CAR-T cell therapy market is expected to increase as the incidence of cancer rises and the number of patients who fail to respond to alternative therapies rises. If the number of adults and children diagnosed with cancer rises, there will be a greater need for an efficient and dependable clinical care strategy to improve patient care.

With the approval of Kymriah, Yescarta, and Tecartus, some companies have moved away from developing protein and small molecule-based drugs towards adoptive therapies. This has prompted strategic investments in this field by both public and private entities, further propelling the demand for T-cell therapy.

Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-61563?utm_source=hp&utm_medium=openpr&utm_campaign=hp

Furthermore, rising government measures aimed at enhancing health-care facilities and encouraging cancer-cell therapy research is fueling the industry. However, cytokine release syndrome (CRS) and other neurological disorders such as seizures, coma, hallucinations, and delirium are possible side effects of cell therapy. This factor is expected to stifle business expansion.

The industry is taking steps to address challenges in order to encourage the adoption of CAR-T cell therapies. Several CAR-T players have begun to impregnate T cells with CARs using powerful gene-transfer tools. There are numerous examples of collaborations to improve CRISPR and electroporation technologies for T cell modification. To avoid toxicity, some businesses are employing "on-off" switches that can transform CAR-T cells off.

Unfortunately, achieving CAR-T effectiveness against solid tumors has eluded researchers so far, with clinical trials revealing a severely limited response.

Growth Drivers that Support the Global Cart Cell Therapy Market:

• The CAR T cell therapy market has been divided into CD22, CD19, and other, based on target antigens. Over the forecast period, the CD19 target antigen segment will lead the market. The high demand for CD19 in the global cart cell therapy market is due to the increasing need for integrated healthcare systems.

• In 2018, the healthcare industry had the largest share of the enduse market. Cart cell therapy helps to improve disease control, which increases clinical outcomes. As a result, the length of stay in the hospital will be reduced, as will the number of hours spent under physician observation.

• The European Medicines Agency's approval for the use of Kymriah and Yescarta drugs in the region is primarily responsible for the growth of the CAR-T cell therapy industry. Meanwhile, the APAC sector is still in its infancy, with Japan's Ministry of Health, Labor and Welfare (MHLW) becoming the first regulatory body to approve Kymriah administration.

• In the global cart cell therapy industry, North America is the market leader. The region's dominance can be attributed to favourable government policies for disease prevention and HCIT adoption, increased support for population health management, growing chronic disease prevalence, and the availability of a well-developed healthcare infrastructure.

• Because of rising disposable income and developing healthcare infrastructure, China's CAR T cell therapy market is expected to expand significantly over the forecast period. In addition, a growing number of CAR T cell therapy industry companies are signing and partnering on research and manufacturing contracts with regional players for these therapies, which is boosting market growth.

• Cesca Therapeutics, for example, signed a contract with Boyalife Group in China in March 2018 for CAR-T cell manufacturing, production, and bioprocessing.

Recent Developments in the Global Cart Cell Therapy Market:

• The FDA approved Kite Pharma's brexucabtagene autoleucel, marketed as Tecartus, as the third CAR-T cell therapy in July 2020. It is the first CAR-T therapy to be approved for the treatment of relapsed or refractory mantle cell lymphoma (MCL). The approval of these early CAR-T cell therapies has paved the way for many other forms of cell and gene therapies to gain acceptance from regulators and the scientific and medical community.

Speak to analyst before buying this report: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-61563?utm_source=hp&utm_medium=openpr&utm_campaign=hp

Major companies functioning in the global Cart Cell Therapy Market are Kite Pharma, Novartis AG, Mustang Bio, CARsgen Therapeutics, Sorrento Therapeutics, Autolus Therapeutics, Cellectis, Pfizer Inc., Legend Biotech, and others.

Market Segmentation:

By Target Antigen
• CD19
• CD22
• Others

By Application
• Acute Lymphoblastic Leukemia
• Diffuse Large B-Cell Lymphoma
• Others

By End User
• Pharmaceuticals Companies
• Hospital
• Clinic
• Other

By Region:

North America
o By Country (US, Canada, Mexico)
o By Target Antigen
o By Application
o By End User

Western Europe
o By Country (Germany, UK, France, Italy, Spain, Rest of Western Europe)
o By Target Antigen
o By Application
o By End User

Eastern Europe
o By Country (Russia, Turkey, Rest of Eastern Europe)
o By Target Antigen
o By Application
o By End User

Asia Pacific
o By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
o By Target Antigen
o By Application
o By End User

Middle East
o By Country (UAE, Saudi Arabia, Qatar, Iran, Rest of Middle East)
o By Target Antigen
o By Application
o By End User

Rest of the World
o By Region (South America, Africa)
o By Target Antigen
o By Application
o By End User

Contact:
Quince Market Insights
Office No- A109
Pune, Maharashtra 411028
Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986
Email: sales@quincemarketinsights.com
Web: www.quincemarketinsights.com

ABOUT US:
QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world's most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

This release was published on openPR.